









Markets
/
Stocks
/
nasdaq-uthr
/

United Therapeutics Corp

UTHR

View Detailed Chart

297.288USD

-2.872-0.96%

Market hours （ET）Quotes delayed by 15 min

13.40BMarket Cap

11.07P/E TTM



United Therapeutics Corp

297.288

-2.872-0.96%

Overview Company Financials

Financials

Intraday

30m

Today

-0.96%

5 Days

+0.95%

1 Month

+5.66%

6 Months

-18.54%

Year to Date

-15.74%

1 Year

-9.71%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 15 analysts

BUY

Current Rating

380.932

Target Price

26.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

170

Total

Median

Average

Company name

Ratings

Analysts

United Therapeutics Corp

UTHR

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(2)

Buy(4)

Indicators

Sell(1)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

3.809

Neutral

RSI(14)

54.158

Neutral

STOCH(KDJ)(9,3,3)

87.675

Overbought

ATR(14)

7.178

Low Volatility

CCI(14)

145.329

Buy

Williams %R

8.051

Overbought

TRIX(12,20)

-0.174

Sell

StochRSI(14)

95.650

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

296.004

Buy

MA10

292.186

Buy

MA20

289.402

Buy

MA50

301.156

Sell

MA100

306.747

Sell

MA200

335.911

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Ticker SymbolUTHR

CompanyUnited Therapeutics Corp

CEODr. Martine A. Rothblatt

Websitehttps://www.unither.com/